Are Analysts Bullish about Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) after last week?

July 27, 2018 - By Jason Dias

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) LogoInvestors sentiment decreased to 0.93 in Q1 2018. Its down 0.47, from 1.4 in 2017Q4. It worsened, as 32 investors sold Pacira Pharmaceuticals, Inc. shares while 51 reduced holdings. 28 funds opened positions while 49 raised stakes. 41.78 million shares or 4.29% more from 40.06 million shares in 2017Q4 were reported.
Credit Suisse Ag accumulated 0% or 44,898 shares. Consonance Cap Mngmt Limited Partnership owns 2.63 million shares for 7.5% of their portfolio. Td Asset Management owns 29,100 shares. Ubs Asset Mngmt Americas Inc holds 25,931 shares or 0% of its portfolio. Stifel Financial reported 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). State Of Wisconsin Inv Board reported 39,400 shares. Schroder Group Inc Inc invested in 0.07% or 1.23 million shares. Jpmorgan Chase, a New York-based fund reported 8,543 shares. 195,274 were reported by Schwab Charles Inv. Public Employees Retirement Association Of Colorado reported 0.06% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Raymond James And holds 0% or 17,761 shares. 65,000 were accumulated by California Employees Retirement. Aqr Cap Management Limited Co reported 89,828 shares. Great West Life Assurance Can accumulated 3,835 shares. Cap Fund Mgmt Sa owns 6,701 shares.

Since May 15, 2018, it had 0 buys, and 8 insider sales for $1.71 million activity. $667,764 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by STACK DAVID M on Wednesday, June 6. $12,316 worth of stock was sold by Weiland Robert J. on Monday, June 4. On Monday, June 4 the insider Scranton Richard sold $45,138. HASTINGS PAUL J sold $26,137 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Monday, June 4. 708 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares with value of $23,378 were sold by Reinhart Charles A. III. Riker Lauren Bullaro also sold $26,449 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Monday, June 4.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

Among 13 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 7 have Buy rating, 1 Sell and 5 Hold. Therefore 54% are positive. Pacira Pharmaceuticals had 29 analyst reports since January 29, 2018 according to SRatingsIntel. The firm has “Hold” rating given on Monday, January 29 by Canaccord Genuity. Wedbush maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Monday, April 30 with “Buy” rating. Mizuho maintained the shares of PCRX in report on Monday, February 5 with “Hold” rating. The firm has “Buy” rating by Piper Jaffray given on Tuesday, February 13. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Hold” rating by Canaccord Genuity on Monday, April 9. On Wednesday, March 7 the stock rating was maintained by Wedbush with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, March 1. The rating was maintained by Mizuho with “Hold” on Monday, April 9. The rating was maintained by Piper Jaffray on Monday, April 9 with “Buy”. The stock has “Hold” rating by Needham on Friday, February 16. Below is a list of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) latest ratings and price target changes.

21/06/2018 Broker: Janney Capital Rating: Sell New Target: $27.0000 Maintain
18/06/2018 Broker: Wedbush Rating: Buy New Target: $80.0000 Maintain
29/05/2018 Broker: Mizuho Rating: Hold New Target: $31.0000 Maintain
04/05/2018 Broker: JMP Securities Rating: Buy New Target: $56.0000
03/05/2018 Broker: Mizuho Rating: Hold New Target: $31.0000 Maintain
03/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $48.0000 Maintain
30/04/2018 Broker: Wedbush Rating: Buy New Target: $80.0000 Maintain
10/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $40 New Target: $43 Maintain
09/04/2018 Broker: Mizuho Rating: Hold New Target: $31.0000 Maintain
09/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $48.0000 Maintain

The stock increased 12.55% or $4.55 during the last trading session, reaching $40.8. About 1.64 million shares traded or 159.87% up from the average. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has declined 23.22% since July 27, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.66 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

More recent Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news were published by: Nasdaq.com which released: “Pacira to Report Second Quarter 2018 Financial Results on Thursday August 2, 2018” on July 25, 2018. Also Seekingalpha.com published the news titled: “Pacira reports preliminary Q2 sales, shares up 2.5%” on July 10, 2018. Fool.com‘s news article titled: “Why Pacira Pharmaceuticals Stock Is on the Rise Today” with publication date: July 26, 2018 was also an interesting one.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.